Provisional agenda

1. Opening of the session and adoption of the agenda
   Documents EB138/1 Rev.1 and EB138/1 (annotated)

2. Report by the Director-General
   Document EB138/2

3. Report of the Programme, Budget and Administration Committee of the Executive Board
   Document EB138/3

4. Report of the regional committees to the Executive Board
   Document EB138/4

5. WHO reform
   5.1 Overview of reform implementation
       Document EB138/5
   5.2 Member State consultative process on governance reform
       Document EB138/6
   5.3 Framework of engagement with non-State actors
       Document EB138/7

6. Noncommunicable diseases
   6.1 Maternal, infant and young child nutrition
       Document EB138/8
   6.2 Draft global plan of action on violence
       Document EB138/9
6.3 Prevention and control of noncommunicable diseases: responses to specific assignments in preparation for the third High-level Meeting of the United Nations General Assembly on the Prevention and Control of Non-communicable diseases in 2018

Document EB138/10

6.4 Public health dimension of the world drug problem including in the context of the Special Session of the United Nations General Assembly on the World Drug Problem, to be held in 2016

Document EB138/11


Document EB138/12

7. Promoting health through the life course

7.1 Monitoring of the achievement of the health-related Millennium Development Goals

Document EB138/13

7.2 Health in the 2030 Agenda for Sustainable Development

Document EB138/14

7.3 Operational plan to take forward the Global Strategy on Women’s, Children’s and Adolescents’ Health

Document EB138/15

7.4 Multisectoral action for a life course approach to healthy ageing: draft global strategy and plan of action on ageing and health

Document EB138/16

7.5 Health and the environment: draft roadmap for an enhanced global response to the adverse health effects of air pollution

Document EB138/17

7.6 Role of the health sector in the sound management of chemicals

Document EB138/18
8. **Preparedness, surveillance and response**

8.1 Implementation of the International Health Regulations (2005)

Document [EB138/19](#)


Document [EB138/20](#)

8.2 Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits

Documents [EB138/21](#) and [EB138/21 Add.1](#)

8.3 Smallpox eradication: destruction of variola virus stocks

Document [EB138/22](#)

8.4 WHO response in severe, large-scale emergencies

Document [EB138/23](#)

8.5 Global action plan on antimicrobial resistance

Document [EB138/24](#)

8.6 Poliomyelitis

Document [EB138/25](#)

8.7 Promoting the health of migrants

Document [EB138/26](#)

9. **Communicable diseases**

9.1 2014 Ebola virus disease outbreak and issues raised: follow-up to the Special Session of the Executive Board on the Ebola Emergency (resolution EBSS3.R1) and the Sixty-eighth World Health Assembly (decision WHA68(10))

- Update on 2014 Ebola virus disease outbreak and Secretariat response to other issues raised

Document [EB138/27](#)

- Options for strengthening information-sharing on diagnostic, preventive and therapeutic products and for enhancing WHO’s capacity to facilitate access to these products, including the establishment of a global database, starting with haemorrhagic fevers

Document [EB138/28](#)
9.2 Draft global health sector strategies

- HIV, 2016–2021
  Document EB138/29
- Viral hepatitis, 2016–2021
  Document EB138/30
- Sexually transmitted infections, 2016–2021
  Document EB138/31

9.3 Global vaccine action plan

Document EB138/32

9.4 Mycetoma

Document EB138/33

10. Health systems

10.1 Health workforce and services

Documents EB138/34 and EB138/35

- Draft global strategy on human resources for health: workforce 2030
  Document EB138/36
- Framework on integrated people-centred health services
  Document EB138/37

10.2 Comprehensive evaluation of the global strategy and plan of action on public health, innovation and intellectual property: progress update

Document EB138/38

10.3 Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination – Planning for an open-ended meeting of Member States to discuss progress

Document EB138/39

10.4 Substandard/spurious/falsely-labelled/falsified/counterfeit medical products

Document EB138/40

10.5 Addressing the global shortages of medicines, and the safety and accessibility of children’s medication

Document EB138/41
11. **Financial matters**

11.1 Financing of Programme budget 2016–2017

Document EB138/42

11.2 Scale of assessments

Document EB138/43

11.3 Amendments to the Financial Regulations and Financial Rules [if any]

12. **Management and legal matters**

12.1 Evaluation: update and proposed workplan for 2016–2017

Document EB138/44

12.2 Real estate: update on the Geneva buildings renovation strategy

Document EB138/45

12.3 Process for the election of the Director-General of the World Health Organization

Document EB138/46

12.4 Hosted health partnerships

Documents EB138/47, EB138/47 Add.1 and EB138/47 Add.2

12.5 Reports of committees of the Executive Board

- Standing Committee on Nongovernmental Organizations

  Document EB138/48

- Foundations and awards

  Document EB138/49

12.6 Provisional agenda of the Sixty-ninth World Health Assembly and date, place and draft provisional agenda of the 139th session of the Executive Board

Document EB138/50

13. **Staffing matters**

13.1 Human resources: annual report

Documents EB138/51 and EB138/51 Add.1
13.2 Report of the International Civil Service Commission

Document EB138/52

13.3 Amendments to the Staff Regulations and Staff Rules

Document EB138/54

13.4 Statement by the representative of the WHO staff associations

Document EB138/INF./1

14. Matters for information

14.1 Reports of advisory bodies

• Expert committees and study groups

Documents EB138/53 and EB138/53 Add.1

15. Closure of the session

Note: in line with resolution WHA67.2, the following items will be considered by the Health Assembly under progress reports.

<table>
<thead>
<tr>
<th>Eradication of dracunculiasis (resolution WHA64.16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO strategy on research for health (resolution WHA63.21)</td>
</tr>
<tr>
<td>Implementation of the Framework for Country Action across Sectors for Health and Health Equity (resolution WHA67.12)</td>
</tr>
<tr>
<td>Access to biotherapeutic products, including similar biotherapeutic products, and ensuring their quality, safety and efficacy (resolution WHA67.21)</td>
</tr>
<tr>
<td>Access to essential medicines (resolution WHA67.22)</td>
</tr>
<tr>
<td>Health intervention and technology assessment in support of universal health coverage (resolution WHA67.23)</td>
</tr>
<tr>
<td>Reproductive health: strategy to accelerate progress towards the attainment of international development goals and targets (resolution WHA57.12)</td>
</tr>
<tr>
<td>Contributing to social and economic development: sustainable action across sectors to improve health and health equity [follow-up of the 8th Global Conference on Health Promotion] (resolution WHA67.12)</td>
</tr>
<tr>
<td>Strengthening of palliative care as a component of comprehensive care throughout the life course (resolution WHA67.19)</td>
</tr>
<tr>
<td>Sustaining the elimination of iodine deficiency disorders (resolution WHA60.21)</td>
</tr>
<tr>
<td>Multilingualism: implementation of action plan (resolution WHA61.12)</td>
</tr>
</tbody>
</table>

= = =